ClinicalTrials.gg
CompletedNCT01391546Updated Jan 9, 2019Results posted

Immunogenicity and Safety Study of ZOSTAVAX Administered by Intramuscular or Subcutaneous Route to Participants Aged From 50 Years Old (V211-045)

A Phase 3 interventional study of ZOSTAVAX in Herpes Zoster, sponsored by Merck Sharp & Dohme LLC. Completed. Open to participants aged 50 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2019-01-09.

Sponsored by Merck Sharp & Dohme LLC (part of Merck & Co., Inc) · Phase 3, Interventional, and Prevention

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
354
Allocation
Randomized
Ages
50 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 29 studies testing Chickenpox Vaccine in Herpes Zoster — none open to participants now, none under way, none of them phase 3. Chickenpox Vaccine · Herpes Zoster.

Enrollment
9th of 29
354 · median 160
Started
2011
with 3 others
Phase 3
9 of 29
none open now
Registered
15th of 29
by date
Lead sponsor
15 of 29
Merck Sharp & Dohme LLC

Among the 29 studies testing Chickenpox Vaccine in Herpes Zoster, this one is the 9th largest by enrollment, is one of 4 that started in 2011, is one of 9 in phase 3, and was the 15th registered.

Herpes Zoster

299 studies on the registry are indexed under Herpes Zoster; 55 are open to participants now.

Browse Herpes Zoster studies →

Open to participants now

None of the 29 studies testing Chickenpox Vaccine in Herpes Zoster is open now. The open studies under Herpes Zoster, anywhere →

About Chickenpox Vaccine

Chickenpox Vaccine: first FDA approval 1995 (Varivax). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 37 Herpes Zoster studies recruiting now, 26 (70%) set no upper age limit and 6 (16%) stop at 75 or younger; 3 take children under 18; 13 take healthy volunteers.

This study: 50 Years and older · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 29 studies testing Chickenpox Vaccine in Herpes Zoster as a file.
02

Study summary

PRIMARY OBJECTIVES

Two co-primary objectives are:

  • To demonstrate that the immunogenicity of ZOSTAVAX administered by intramuscular route (IM) is non-inferior to ZOSTAVAX administered by subcutaneous route (SC)
  • To demonstrate that ZOSTAVAX administered by IM route induces an acceptable fold-rise of varicella zoster virus (VZV) antibody titre from pre to 4-week post-vaccination

SECONDARY OBJECTIVES

Immunogenicity objectives

  • To evaluate the immunogenicity as measured by VZV antibody titre at 4 weeks following ZOSTAVAX administered by IM or SC route
  • To evaluate the immune response as measured by a second assay, the VZV Interferon gamma Enzyme-linked immunospot (ELISPOT) at 4 weeks following ZOSTAVAX administered by IM or SC route

Safety objective

  • To describe the safety profile of ZOSTAVAX administered by IM or SC route
03

Conditions studied

  • Herpes Zoster

Browse trials for

04

Who can participate

Ages eligible
50 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adults aged >=50 years
  • Varicella history-positive or residence for >30 years in a country with endemic VZV infection

Exclusion criteria

Exclusion Criteria:

  • Febrile illness
  • History of or anaphylactoid reaction to any of the vaccine components
  • Prior herpes zoster episode clinically diagnosed or exposure to varicella or herpes zoster within the 4 weeks prior to vaccination
  • Prior receipt of varicella or zoster vaccine
  • Active untreated tuberculosis
  • Thrombocytopenia, any other coagulation disorder contraindicating intramuscular injection
  • Receipt of medication / vaccine that may interfere with study assessments
  • Known or suspected immune dysfunction
  • User of recreational / illicit drugs or subject with alcohol abuse or dependence within the last year
  • Any condition that might interfere with the interpretation of the study,
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 3
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
354 participants (actual)

Study arms

  • Experimental
    ZOSTAVAX intramuscular (IM) route

    Single dose of 0.65 mL via IM injection

    Biological: ZOSTAVAX

  • Active comparator
    ZOSTAVAX subcutaneous (SC) route

    Single dose of 0.65 mL via SC injection

    Biological: ZOSTAVAX

Interventions

  • BiologicalZOSTAVAX

    1 dose 0.65 mL

    Also known as: V211

06

What researchers measure

Primary outcomes

  1. Geometric Mean Titre (GMT) of Varicella Zoster Virus (VZV) Antibodies 4 Weeks Post-vaccination

    Blood samples taken at 4 weeks post vaccination to determine the geometric mean titre (GMT) of VZV antibodies via Glycoprotein Enzyme Linked Immunosorbent Assay (gpELISA).

    Time frame: 4 week post-vaccination

  2. Geometric Mean Fold Rise (GMFR) in VZV Antibody Titre: IM Route

    Blood sample taken at predose (Day 0) and 4 weeks post vaccination to determine the geometric mean titre (GMT) of VZV antibodies via gpELISA. The GMFR was calculated as GMT Post-dose/GMT Pre-vaccination

    Time frame: Pre-vaccination (Day 0) and 4 week post-vaccination

Secondary outcomes

  1. Geometric Mean Fold Rise (GMFR) in VZV Antibody Titre: SC Route

    Blood sample taken at predose (Day 0) and 4 weeks post vaccination to determine the geometric mean titre (GMT) of VZV antibodies via gpELISA. The GMFR was calculated as GMT Post-vaccination/GMT Pre-vaccination

    Time frame: Pre-vaccination (Day 0) and 4 week post-vaccination

  2. Geometric Mean Count (GMCs) of VZV Interferon Gamma ((IFN-γ) Enzyme-Linked ImmunoSpot (ELISPOT) Antibodies

    Blood samples taken 4 weeks post-vaccination to determine the IFN-γ ELISPOT GMC's. Results were reported as ELISPOT count/10\^6 Peripheral Blood Mononuclear Cells (PBMC)

    Time frame: 4 week post-vaccination

  3. Geometric Mean Fold Rise (GMFR) of IFN-γ ELISPOT Antibodies

    Blood samples taken pre-vaccination and 4 weeks post-vaccination to determine the IFN-γ ELISPOT GMFR.

    Time frame: Pre-vaccination (Day 0) and 4 week post-vaccination

  4. Percentage of Participants Who Report at Least 1 Injection-site Adverse Reaction

    Participants entered data into daily diary card regarding previously identified possible injection site reactions of erythema, injection site swelling or injection site pain for 1st 4 days post-vaccination. Additionally, injection site reactions not prompted on diary card (unsolicited) were collected up 28 days post-vaccination. All injection site reactions (solicited or unsolicited) were recorded.

    Time frame: up to 28 days after vaccination

  5. Percentage of Participants Who Report at Least 1 Systemic Adverse Event

    An adverse event (AE) was defined as any unfavorable and unintended change in the structure, function, or chemistry of the body temporally associated with the use of the study drug, whether or not considered related to the use of the product. Adverse events that were considered systemic (not localized) were summarized. These events included rashes of interest: i.e. Varicella, Varicella-like rashes, Herpes zoster or shingles and Herpes zoster-like rashes and other systemic adverse events.

    Time frame: up to Day 28 after vaccination

  6. Percentage of Participants Who Report at Least 1 Serious Adverse Event

    A serious adverse event (SAE) is any adverse event that results in death, is life threatening, results in a persistent or significant disability/incapacity, results in hospitalization or prolongs an existing hospitalization, is a congenital anomaly/birth defect, is a cancer, is an overdose, or is considered an "other important medical event" based on medical judgement. The percentage of participants who reported an SAE within 35 days of vaccination were recorded.

    Time frame: up to 35 days after vaccination

07

Results

Posted Nov 20, 2017

Participant flow

Participant flow — Overall Study
MilestoneZOSTAVAX Intramuscular (IM) RouteZOSTAVAX Subcutaneous (SC) Route
Started177177
Vaccinated176177
Completed176177
Not completed10
Withdrew: History of herpes zoster (hz)10

Outcome measures

PrimaryGeometric Mean Titre (GMT) of Varicella Zoster Virus (VZV) Antibodies 4 Weeks Post-vaccination

Blood samples taken at 4 weeks post vaccination to determine the geometric mean titre (GMT) of VZV antibodies via Glycoprotein Enzyme Linked Immunosorbent Assay (gpELISA).

Time frame:
4 week post-vaccination
Reported as:
Geometric mean · gpELISA units/mL
Geometric Mean Titre (GMT) of Varicella Zoster Virus (VZV) Antibodies 4 Weeks Post-vaccination
gpELISA units/mLZOSTAVAX Intramuscular (IM) RouteZOSTAVAX Subcutaneous (SC) Route
Geometric Mean Titre (GMT) of Varicella Zoster Virus (VZV) Antibodies 4 Weeks Post-vaccination395.3 (350.6 to 445.6)391.7 (348.9 to 439.7)
Statistical analysis
  • ZOSTAVAX Intramuscular (IM) Route vs ZOSTAVAX Subcutaneous (SC) Route · longitudinal regression model · p = <0.001 · Gmt ratio: 1.05 · 95% CI 0.93 to 1.18GMT ratio = GMT IM route divided by GMT SC route
PrimaryGeometric Mean Fold Rise (GMFR) in VZV Antibody Titre: IM Route

Blood sample taken at predose (Day 0) and 4 weeks post vaccination to determine the geometric mean titre (GMT) of VZV antibodies via gpELISA. The GMFR was calculated as GMT Post-dose/GMT Pre-vaccination

Time frame:
Pre-vaccination (Day 0) and 4 week post-vaccination
Reported as:
Geometric mean · Ratio
Geometric Mean Fold Rise (GMFR) in VZV Antibody Titre: IM Route
RatioZOSTAVAX Intramuscular (IM) Route
Geometric Mean Fold Rise (GMFR) in VZV Antibody Titre: IM Route2.7 (2.4 to 3.0)
Statistical analysis
  • ZOSTAVAX Intramuscular (IM) Route · Gmfr: 2.7 · 95% CI 2.4 to 3.0GMFR = GMT Post-vaccination/GMT Pre-vaccination
SecondaryGeometric Mean Fold Rise (GMFR) in VZV Antibody Titre: SC Route

Blood sample taken at predose (Day 0) and 4 weeks post vaccination to determine the geometric mean titre (GMT) of VZV antibodies via gpELISA. The GMFR was calculated as GMT Post-vaccination/GMT Pre-vaccination

Time frame:
Pre-vaccination (Day 0) and 4 week post-vaccination
Reported as:
Geometric mean · Ratio
Geometric Mean Fold Rise (GMFR) in VZV Antibody Titre: SC Route
RatioZOSTAVAX Subcutaneous (SC) Route
Geometric Mean Fold Rise (GMFR) in VZV Antibody Titre: SC Route2.5 (2.2 to 2.8)
SecondaryGeometric Mean Count (GMCs) of VZV Interferon Gamma ((IFN-γ) Enzyme-Linked ImmunoSpot (ELISPOT) Antibodies

Blood samples taken 4 weeks post-vaccination to determine the IFN-γ ELISPOT GMC's. Results were reported as ELISPOT count/10\^6 Peripheral Blood Mononuclear Cells (PBMC)

Time frame:
4 week post-vaccination
Reported as:
Geometric mean · ELISPOT count/10^6 PBMC
Geometric Mean Count (GMCs) of VZV Interferon Gamma ((IFN-γ) Enzyme-Linked ImmunoSpot (ELISPOT) Antibodies
ELISPOT count/10^6 PBMCZOSTAVAX Intramuscular (IM) RouteZOSTAVAX Subcutaneous (SC) Route
Geometric Mean Count (GMCs) of VZV Interferon Gamma ((IFN-γ) Enzyme-Linked ImmunoSpot (ELISPOT) Antibodies209.8 (175.2 to 251.3)195.7 (161.9 to 236.6)
SecondaryGeometric Mean Fold Rise (GMFR) of IFN-γ ELISPOT Antibodies

Blood samples taken pre-vaccination and 4 weeks post-vaccination to determine the IFN-γ ELISPOT GMFR.

Time frame:
Pre-vaccination (Day 0) and 4 week post-vaccination
Reported as:
Geometric mean · Ratio
Geometric Mean Fold Rise (GMFR) of IFN-γ ELISPOT Antibodies
RatioZOSTAVAX Intramuscular (IM) RouteZOSTAVAX Subcutaneous (SC) Route
Geometric Mean Fold Rise (GMFR) of IFN-γ ELISPOT Antibodies3.3 (2.8 to 3.9)3.4 (2.7 to 4.3)
SecondaryPercentage of Participants Who Report at Least 1 Injection-site Adverse Reaction

Participants entered data into daily diary card regarding previously identified possible injection site reactions of erythema, injection site swelling or injection site pain for 1st 4 days post-vaccination. Additionally, injection site reactions not prompted on diary card (unsolicited) were collected up 28 days post-vaccination. All injection site reactions (solicited or unsolicited) were recorded.

Time frame:
up to 28 days after vaccination
Reported as:
Number · Percentage of Participants
Percentage of Participants Who Report at Least 1 Injection-site Adverse Reaction
Percentage of ParticipantsZOSTAVAX Intramuscular (IM) RouteZOSTAVAX Subcutaneous (SC) Route
Percentage of Participants Who Report at Least 1 Injection-site Adverse Reaction34.1 (27.1 to 41.6)64.4 (56.9 to 71.4)
SecondaryPercentage of Participants Who Report at Least 1 Systemic Adverse Event

An adverse event (AE) was defined as any unfavorable and unintended change in the structure, function, or chemistry of the body temporally associated with the use of the study drug, whether or not considered related to the use of the product. Adverse events that were considered systemic (not localized) were summarized. These events included rashes of interest: i.e. Varicella, Varicella-like rashes, Herpes zoster or shingles and Herpes zoster-like rashes and other systemic adverse events.

Time frame:
up to Day 28 after vaccination
Reported as:
Number · Percentage of Participants
Percentage of Participants Who Report at Least 1 Systemic Adverse Event
Percentage of ParticipantsZOSTAVAX Intramuscular (IM) RouteZOSTAVAX Subcutaneous (SC) Route
Percentage of Participants Who Report at Least 1 Systemic Adverse Event23.3 (17.3 to 30.2)22.6 (16.7 to 29.5)
SecondaryPercentage of Participants Who Report at Least 1 Serious Adverse Event

A serious adverse event (SAE) is any adverse event that results in death, is life threatening, results in a persistent or significant disability/incapacity, results in hospitalization or prolongs an existing hospitalization, is a congenital anomaly/birth defect, is a cancer, is an overdose, or is considered an "other important medical event" based on medical judgement. The percentage of participants who reported an SAE within 35 days of vaccination were recorded.

Time frame:
up to 35 days after vaccination
Reported as:
Number · Percentage of Participants
Percentage of Participants Who Report at Least 1 Serious Adverse Event
Percentage of ParticipantsZOSTAVAX Intramuscular (IM) RouteZOSTAVAX Subcutaneous (SC) Route
Percentage of Participants Who Report at Least 1 Serious Adverse Event0.6 (NA to 3.1)1.1

Adverse events

Collected over up to 35 days. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
ZOSTAVAX Intramuscular (IM) Route—1/176 (0.6%)59/176 (33.5%)
ZOSTAVAX Subcutaneous (SC) Route—2/177 (1.1%)112/177 (63.3%)
Most frequent serious events
Most frequent serious events
EventZOSTAVAX Intramuscular (IM) RouteZOSTAVAX Subcutaneous (SC) Route
Hernia obstructiveGeneral disorders1/1760/177
Humerus fractureInjury, poisoning and procedural complications0/1761/177
Deep vein thrombosisVascular disorders0/1761/177
Most frequent other events
Most frequent other events
EventZOSTAVAX Intramuscular (IM) RouteZOSTAVAX Subcutaneous (SC) Route
Injection site erythemaGeneral disorders29/17694/177
Injection site painGeneral disorders46/17670/177
Injection site swellingGeneral disorders24/17667/177
Injection site pruritusGeneral disorders3/17611/177

Baseline characteristics

Age, Customized
Age, Customized(Participants)ZOSTAVAX Intramuscular (IM) RouteZOSTAVAX Subcutaneous (SC) RouteTotal
50-59 years of age8182163
60-69 years of age5655111
≥70 years of age404080
Sex: Female, Male
Sex: Female, Male(Participants)ZOSTAVAX Intramuscular (IM) RouteZOSTAVAX Subcutaneous (SC) RouteTotal
Female9897195
Male7980159
Age at Vaccination
Age at Vaccination(Years of Age)ZOSTAVAX Intramuscular (IM) RouteZOSTAVAX Subcutaneous (SC) RouteTotal
Mean62.6 ± 8.362.6 ± 8.562.6 ± 8.4
08

Study locations

No study locations are listed for this record.

09

References and documents

Publications

  • Diez-Domingo J, Weinke T, Garcia de Lomas J, Meyer CU, Bertrand I, Eymin C, Thomas S, Sadorge C. Comparison of intramuscular and subcutaneous administration of a herpes zoster live-attenuated vaccine in adults aged >/=50 years: a randomised non-inferiority clinical trial. Vaccine. 2015 Feb 4;33(6):789-95. doi: 10.1016/j.vaccine.2014.12.024. Epub 2014 Dec 30. PubMed 25555381 ↗

Individual participant data

Plan to share: Yes — http://engagezone.msd.com/doc/ProcedureAccessClinicalTrialData.pdf

Data sharing details ↗ · engagezone.msd.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jun 2011 to primary completion in Oct 2012, 15 months.

Results were first posted in Nov 2017, 5 years 1 month after primary completion.

Of 33 industry-sponsored phase 3 interventional studies under Herpes Zoster, half reached primary completion within 16 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 45. This study's 15 months is close to that.

Counting every sponsor, half of 40 studies reached it within 16 months; a quarter within 10 and three quarters within 45.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 7, 2011
First posted
Jul 12, 2011
StartActual
Jun 20, 2011
Primary completionActual
Oct 15, 2012
CompletionActual
Oct 15, 2012
Results first posted
Nov 20, 2017
Last update
Jan 9, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 9, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01391546
Responsible party
Sponsor
First posted
Jul 12, 2011
Start date
Jun 20, 2011
Primary completion
Oct 15, 2012
Completion
Oct 15, 2012
Results posted
Nov 20, 2017
Last update
Jan 9, 2019

Study contacts

Medical Director
study director · Merck Sharp & Dohme LLC

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Chickenpox Vaccine

Start the discussion